Heart failure in 10 years time: focus on pharmacological treatment.
作者信息
McMurray J J V
机构信息
Department of Cardiology, Western Infirmary, Glasgow G11 6NT, UK.
出版信息
Heart. 2002 Oct;88 Suppl 2(Suppl 2):ii40-6. doi: 10.1136/heart.88.suppl_2.ii40.
Abstract
摘要
相似文献
1
Heart failure in 10 years time: focus on pharmacological treatment.
Heart. 2002 Oct;88 Suppl 2(Suppl 2):ii40-6. doi: 10.1136/heart.88.suppl_2.ii40.
2
Improving clinical outcomes with drug treatment in heart failure: what have trials taught?
Am J Cardiol. 2003 Mar 20;91(6A):9D-14D. doi: 10.1016/s0002-9149(02)03374-x.
3
Ivabradine and outcomes in chronic heart failure.
Lancet. 2010 Dec 18;376(9758):2069; author reply 2069-70. doi: 10.1016/S0140-6736(10)62285-4.
4
Treatment of chronic heart failure.
Lancet. 1992 Jul 11;340(8811):92-5. doi: 10.1016/0140-6736(92)90406-s.
5
Drugs for chronic heart failure.
Med Lett Drugs Ther. 2015 Jan 19;57(1460):9-13.
6
Using Cardicor as first-line therapy in heart failure : CiBis iii.
Cardiovasc J Afr. 2009 Jan-Feb;20(1):78.
7
Drug therapy in chronic heart failure.
Postgrad Med J. 2003 Nov;79(937):634-42. doi: 10.1136/pmj.79.937.634.
8
[Pharmacological treatment of heart failure].
Nihon Rinsho. 2003 Apr;61 Suppl 4:660-6.
9
Heart failure.
Clin Evid. 2002 Jun(7):57-78.
10
What constitutes optimal neurohumoral antagonism in chronic heart failure?
Heart. 2016 Dec 1;102(23):1922-1932. doi: 10.1136/heartjnl-2015-308039. Epub 2016 Oct 14.
引用本文的文献
1
Candesartan cilexetil: a review of its use in the management of chronic heart failure.
Drugs. 2005;65(4):537-58. doi: 10.2165/00003495-200565040-00007.
本文引用的文献
1
Myocardial gene therapy.
Nature. 2002 Jan 10;415(6868):234-9. doi: 10.1038/415234a.
2
Long-term use of a left ventricular assist device for end-stage heart failure.
N Engl J Med. 2001 Nov 15;345(20):1435-43. doi: 10.1056/NEJMoa012175.
3
Acute hemodynamic effects of conivaptan, a dual V(1A) and V(2) vasopressin receptor antagonist, in patients with advanced heart failure.
Circulation. 2001 Nov 13;104(20):2417-23. doi: 10.1161/hc4501.099313.
4
CHF-1024, a DA2/alpha2 agonist, blunts norepinephrine excretion and cardiac fibrosis in pressure overload.
Cardiovasc Drugs Ther. 2001 Mar;15(2):131-8. doi: 10.1023/a:1011170812267.
5
Changes in notions about heart failure.
Lancet. 2001 Aug 11;358(9280):432-4. doi: 10.1016/S0140-6736(01)05664-1.
6
Electrophysiological effects of dronedarone (SR 33589), a noniodinated amiodarone derivative in the canine heart: comparison with amiodarone.
Br J Pharmacol. 2001 Jul;133(5):625-34. doi: 10.1038/sj.bjp.0704106.
7
Pacing for heart failure.
Lancet. 2001 Apr 21;357(9264):1277-83. doi: 10.1016/s0140-6736(00)04409-3.
8
The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled study.
J Am Coll Cardiol. 2001 Jun 1;37(7):1775-80. doi: 10.1016/s0735-1097(01)01248-7.
9
Effect of carvedilol on survival in severe chronic heart failure.
N Engl J Med. 2001 May 31;344(22):1651-8. doi: 10.1056/NEJM200105313442201.
10
Low-level inotropic stimulation with type III phosphodiesterase inhibitors in patients with advanced symptomatic chronic heart failure receiving beta-blocking agents.
Curr Cardiol Rep. 2001 May;3(3):224-31. doi: 10.1007/s11886-001-0027-8.
Zotero 插件